{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T03:25:52Z","timestamp":1782357952371,"version":"3.54.5"},"reference-count":52,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2013.0882","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:25:18Z","timestamp":1525238718000},"source":"Crossref","is-referenced-by-count":18,"title":["Adrenal Cortical Insufficiency"],"prefix":"10.3238","author":[{"given":"Marcus","family":"Quinkler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Sch\u00f6fl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter K.","family":"Stalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2013,12,23]]},"reference":[{"key":"10.3238\/arztebl.2013.0882_ref1","doi-asserted-by":"crossref","unstructured":"Arlt W, Allolio B: Adrenal insufficiency. Lancet 2003; 361: 1881\u201393.","DOI":"10.1016\/S0140-6736(03)13492-7"},{"key":"10.3238\/arztebl.2013.0882_ref2","doi-asserted-by":"crossref","unstructured":"Betterle C, Morlin L: Autoimmune Addison's disease. Endocr Dev 2011; 20: 161\u201372.","DOI":"10.1159\/000321239"},{"key":"10.3238\/arztebl.2013.0882_ref3","doi-asserted-by":"crossref","unstructured":"Lovas K, Husebye ES: High prevalence and increasing incidence of Addison's disease in western Norway. Clin Endocrinol (Oxf) 2002; 56: 787\u201391.","DOI":"10.1046\/j.1365-2265.2002.t01-1-01552.x"},{"key":"10.3238\/arztebl.2013.0882_ref4","doi-asserted-by":"crossref","unstructured":"Grossman AB: Clinical Review: The diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab 2010; 95: 4855\u201363.","DOI":"10.1210\/jc.2010-0982"},{"key":"10.3238\/arztebl.2013.0882_ref5","doi-asserted-by":"crossref","unstructured":"Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA: Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000; 355: 542\u20135.","DOI":"10.1016\/S0140-6736(99)06290-X"},{"key":"10.3238\/arztebl.2013.0882_ref6","doi-asserted-by":"crossref","unstructured":"Schlaghecke R, Kornely E, Santen RT, Ridderskamp P: The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992; 326: 226\u201330.","DOI":"10.1056\/NEJM199201233260403"},{"key":"10.3238\/arztebl.2013.0882_ref7","doi-asserted-by":"crossref","unstructured":"Dinsen S, Baslund B, Klose M, et al.: Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med 2013; S0953-S6205.","DOI":"10.1016\/j.ejim.2013.05.014"},{"key":"10.3238\/arztebl.2013.0882_ref8","doi-asserted-by":"crossref","unstructured":"Bleicken B, Hahner S, Ventz M, Quinkler M: Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci 2010; 339: 525\u201331.","DOI":"10.1097\/MAJ.0b013e3181db6b7a"},{"key":"10.3238\/arztebl.2013.0882_ref9","doi-asserted-by":"crossref","unstructured":"Plat L, Leproult R, L'Hermite-Baleriaux M, Fery F, Mockel J, Polonsky KS, Van CE: Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 1999; 84: 3082\u201392.","DOI":"10.1210\/jc.84.9.3082"},{"key":"10.3238\/arztebl.2013.0882_ref10","doi-asserted-by":"crossref","unstructured":"Quinkler M, Hahner S: What is the best long-term management strategy for patients with primary adrenal insufficiency? Clin Endocrinol (Oxf) 2012; 76: 21\u20135.","DOI":"10.1111\/j.1365-2265.2011.04103.x"},{"key":"10.3238\/arztebl.2013.0882_ref11","doi-asserted-by":"crossref","unstructured":"Lebbe M, Arlt W: What is the best diagnostic and therapeutic management strategy for an Addison patient during pregnancy? Clin Endocrinol (Oxf) 2013; 78: 497\u2013502.","DOI":"10.1111\/cen.12097"},{"key":"10.3238\/arztebl.2013.0882_ref12","doi-asserted-by":"crossref","unstructured":"Dellinger RP, Levy MM, Rhodes A, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165\u2013228.","DOI":"10.1007\/s00134-012-2769-8"},{"key":"10.3238\/arztebl.2013.0882_ref13","doi-asserted-by":"crossref","unstructured":"Debono M, Ross RJ, Newell-Price J: Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol 2009; 160: 719\u201329.","DOI":"10.1530\/EJE-08-0874"},{"key":"10.3238\/arztebl.2013.0882_ref14","doi-asserted-by":"crossref","unstructured":"Meyer G, Hackemann A, Reusch J, Badenhoop K: Nocturnal hypoglycemia identified by a continuous glucose monitoring system in patients with primary adrenal insufficiency (Addison's Disease). Diabetes Technol Ther 2012 14: 386\u20138.","DOI":"10.1089\/dia.2011.0158"},{"key":"10.3238\/arztebl.2013.0882_ref15","doi-asserted-by":"crossref","unstructured":"Alkatib AA, Cosma M, Elamin MB, et al.: A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab 2009; 94: 3676\u201381.","DOI":"10.1210\/jc.2009-0672"},{"key":"10.3238\/arztebl.2013.0882_ref16","doi-asserted-by":"crossref","unstructured":"Hahner S, Allolio B: Dehydroepiandrosterone to Enhance Physical Performance: Myth and Reality. Endocrinol Metab Clin North Am 2010; 39: 127\u201339.","DOI":"10.1016\/j.ecl.2009.10.008"},{"key":"10.3238\/arztebl.2013.0882_ref17","doi-asserted-by":"crossref","unstructured":"Hahner S, Allolio B: Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab 2009; 23: 167\u201379.","DOI":"10.1016\/j.beem.2008.09.009"},{"key":"10.3238\/arztebl.2013.0882_ref18","doi-asserted-by":"crossref","unstructured":"Hahner S, Loeffler M, Bleicken B, et al.: Epidemiology of adrenal crisis in chronic adrenal insufficiency \u2013 the need for new prevention strategies. Eur J Endocrinol 2010; 162: 597\u2013602.","DOI":"10.1530\/EJE-09-0884"},{"key":"10.3238\/arztebl.2013.0882_ref19","doi-asserted-by":"crossref","unstructured":"Erichsen MM, Lovas K, Fougner KJ, et al.: Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. Eur J Endocrinol 2009; 160: 233\u20137.","DOI":"10.1530\/EJE-08-0550"},{"key":"10.3238\/arztebl.2013.0882_ref20","doi-asserted-by":"crossref","unstructured":"Lovas K, Gjesdal CG, Christensen M, et al.: Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009; 160: 993\u20131002.","DOI":"10.1530\/EJE-08-0880"},{"key":"10.3238\/arztebl.2013.0882_ref21","doi-asserted-by":"crossref","unstructured":"Koetz KR, Ventz M, Diederich S, Quinkler M: Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012; 97: 85\u201392.","DOI":"10.1210\/jc.2011-2036"},{"key":"10.3238\/arztebl.2013.0882_ref22","doi-asserted-by":"crossref","unstructured":"Dullaart RP, Schols JL, van der SG, Zelissen PM, Sluiter WJ, van Beek AP: Glucocorticoid replacement is associated with hypertriglyceridemia, elevated glucose and higher non-HDL cholesterol, and may diminish the association of HDL cholesterol with the \u2013629C > A CETP promoter polymorphism in growth hormone-receiving hypopituitary patients. Clin Endocrinol (Oxf) 2008; 69: 359\u201366.","DOI":"10.1111\/j.1365-2265.2008.03196.x"},{"key":"10.3238\/arztebl.2013.0882_ref23","doi-asserted-by":"crossref","unstructured":"Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G: The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006; 91: 3954\u201361.","DOI":"10.1210\/jc.2006-0524"},{"key":"10.3238\/arztebl.2013.0882_ref24","doi-asserted-by":"crossref","unstructured":"Hahner S, Loeffler M, Fassnacht M, et al.: Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 2007; 92: 3912\u201322.","DOI":"10.1210\/jc.2007-0685"},{"key":"10.3238\/arztebl.2013.0882_ref25","doi-asserted-by":"crossref","unstructured":"Bleicken B, Hahner S, Loeffler M, Ventz M, Allolio B, Quinkler M: Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 2008; 159: 811\u20137.","DOI":"10.1530\/EJE-08-0578"},{"key":"10.3238\/arztebl.2013.0882_ref26","doi-asserted-by":"crossref","unstructured":"Bleicken B, Hahner S, Loeffler M, et al.: Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2010; 72: 297\u2013304.","DOI":"10.1111\/j.1365-2265.2009.03596.x"},{"key":"10.3238\/arztebl.2013.0882_ref27","doi-asserted-by":"crossref","unstructured":"Lovas K, Husebye ES: Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol 2007; 157: 109\u201312.","DOI":"10.1530\/EJE-07-0052"},{"key":"10.3238\/arztebl.2013.0882_ref28","doi-asserted-by":"crossref","unstructured":"Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G: Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 2006; 91: 4849\u201353.","DOI":"10.1210\/jc.2006-0076"},{"key":"10.3238\/arztebl.2013.0882_ref29","doi-asserted-by":"crossref","unstructured":"Smans LC, Souverein PC, Leufkens HG, Hoepelman AI, Zelissen PM: Increased use of antimicrobial agents and hospital admission for infections in patients with primary adrenal insufficiency: a cohort study. Eur J Endocrinol 2013; 168: 609\u201314.","DOI":"10.1530\/EJE-12-0879"},{"key":"10.3238\/arztebl.2013.0882_ref30","doi-asserted-by":"crossref","unstructured":"Rosen T, Bengtsson BA: Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285\u20138.","DOI":"10.1016\/0140-6736(90)91812-O"},{"key":"10.3238\/arztebl.2013.0882_ref31","doi-asserted-by":"crossref","unstructured":"Gaillard RC, Mattsson AF, Akerblad AC, et al.: Overall and cause-specific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol 2012; 166: 1069\u201377.","DOI":"10.1530\/EJE-11-1028"},{"key":"10.3238\/arztebl.2013.0882_ref32","doi-asserted-by":"crossref","unstructured":"Sherlock M, Ayuk J, Tomlinson JW, et al.: Mortality in patients with pituitary disease. Endocr Rev 2010; 31: 301\u201342.","DOI":"10.1210\/er.2009-0033"},{"key":"10.3238\/arztebl.2013.0882_ref33","doi-asserted-by":"crossref","unstructured":"Sherlock M, Reulen RC, Alonso AA, et al.: ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab 2009; 94: 4216\u201323.","DOI":"10.1210\/jc.2009-1097"},{"key":"10.3238\/arztebl.2013.0882_ref34","doi-asserted-by":"crossref","unstructured":"Repping-Wuts HJ, Stikkelbroeck NM, Noordzij A, Kerstens M, Hermus AR: A glucocorticoid education group meeting: an effective strategy for improving self-management to prevent adrenal crisis. Eur J Endocrinol 2013; 169: 17\u201322.","DOI":"10.1530\/EJE-12-1094"},{"key":"10.3238\/arztebl.2013.0882_ref35","doi-asserted-by":"crossref","unstructured":"Hahner S, Burger-Stritt S, Allolio B: Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur J Endocrinol 2013; 169: 147\u201354.","DOI":"10.1530\/EJE-12-1057"},{"key":"10.3238\/arztebl.2013.0882_ref36","doi-asserted-by":"crossref","unstructured":"Johannsson G, Nilsson AG, Bergthorsdottir R, et al.: Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 2012; 97: 473\u201381.","DOI":"10.1016\/j.yend.2012.05.055"},{"key":"10.3238\/arztebl.2013.0882_ref37","doi-asserted-by":"crossref","unstructured":"Langenheim J, Ventz M, Hinz A, Quinkler M: Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Horm Metab Res 2013; 45: 96\u2013101.","DOI":"10.1055\/s-0032-1316293"},{"key":"10.3238\/arztebl.2013.0882_ref38","doi-asserted-by":"crossref","unstructured":"Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJ: Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf) 2008; 68: 130\u20135.","DOI":"10.1111\/j.1365-2265.2007.03011.x"},{"key":"10.3238\/arztebl.2013.0882_ref39","doi-asserted-by":"crossref","unstructured":"Debono M, Ghobadi C, Rostami-Hodjegan A, et al.: Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 2009; 94: 1548\u201354.","DOI":"10.1210\/jc.2008-2380"},{"key":"10.3238\/arztebl.2013.0882_ref40","doi-asserted-by":"crossref","unstructured":"Merza Z, Rostami-Hodjegan A, Memmott A, et al.: Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2006; 65: 45\u201350.","DOI":"10.1111\/j.1365-2265.2006.02544.x"},{"key":"10.3238\/arztebl.2013.0882_ref41","doi-asserted-by":"crossref","unstructured":"Willis AC, Vince FP: The prevalence of Addison's disease in Coventry, UK. Postgrad Med J 1997; 73: 286\u20138.","DOI":"10.1136\/pgmj.73.859.286"},{"key":"10.3238\/arztebl.2013.0882_ref42","doi-asserted-by":"crossref","unstructured":"Myhre AG, Undlien DE, Lovas K, et al.: Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 2002; 87: 618\u201323.","DOI":"10.1210\/jcem.87.2.8192"},{"key":"10.3238\/arztebl.2013.0882_ref43","doi-asserted-by":"crossref","unstructured":"Reimondo G, Bovio S, Allasino B, Terzolo M, Angeli A: Secondary hypoadrenalism. Pituitary 2008; 11: 147\u201354.","DOI":"10.1007\/s11102-008-0108-4"},{"key":"10.3238\/arztebl.2013.0882_ref44","doi-asserted-by":"crossref","unstructured":"Axelrod L: Glucocorticoid therapy. Medicine (Baltimore) 1976; 55: 39\u201365.","DOI":"10.1097\/00005792-197601000-00003"},{"key":"10.3238\/arztebl.2013.0882_ref45","doi-asserted-by":"crossref","unstructured":"Husebye E, Lovas K: Pathogenesis of primary adrenal insufficiency. Best Pract Res Clin Endocrinol Metab 2009; 23: 147\u201357.","DOI":"10.1016\/j.beem.2008.09.004"},{"key":"10.3238\/arztebl.2013.0882_ref46","doi-asserted-by":"crossref","unstructured":"Schofl C, von zur MA: Vermeidung unerw\u00fcnschter Wirkungen einer Glukokortikoidtherapie [Preventing adverse side-effects of glucocorticoid therapy]. Internist 1997; 38: 371\u20138.","DOI":"10.1007\/s001080050050"},{"key":"10.3238\/arztebl.2013.0882_ref47","unstructured":"Addison T: On the constitutional and local effects of disease of the supra-renal capsules; London: Samuel Highley, 1855."},{"key":"10.3238\/arztebl.2013.0882_ref48","doi-asserted-by":"crossref","unstructured":"Caldato MC, Fernandes VT, Kater CE: One-year clinical evaluation of single morning dose prednisolone therapy for 21-hydroxylase deficiency. Arq Bras Endocrinol Metabol 2004; 48: 705\u201312.","DOI":"10.1590\/S0004-27302004000500017"},{"key":"10.3238\/arztebl.2013.0882_ref49","doi-asserted-by":"crossref","unstructured":"Marik PE, Pastores SM, Annane D, et al.: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36: 1937\u201349.","DOI":"10.1097\/CCM.0b013e31817603ba"},{"key":"10.3238\/arztebl.2013.0882_ref50","doi-asserted-by":"crossref","unstructured":"Fujita Y, Kitamura T, Otsuki M, et al.: Exenatide alters absorption of hydrocortisone in a diabetic patient with panhypopituitarism: iatrogenic adrenal insufficiency. Diabetes Care 2013; 36: e8. doi: 10.2337\/dc12\u20131499.","DOI":"10.2337\/dc12-1499"},{"key":"10.3238\/arztebl.2013.0882_ref51","doi-asserted-by":"crossref","unstructured":"Hazeldine J, Arlt W, Lord JM: Dehydroepiandrosterone as a regulator of immune cell function. J Steroid Biochem Mol Biol 2010; 120: 127\u201336.","DOI":"10.1016\/j.jsbmb.2009.12.016"},{"key":"10.3238\/arztebl.2013.0882_ref52","unstructured":"Dahlqvist P, Bensing S, Ekwall O, Wahlberg J, Bergthorsdottir R, Hulting AL: [A national medical emergency card for adrenal insufficiency. A new warning card for better management and patient safety]. Lakartidningen 2011; 108: 2226\u20137."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T09:22:44Z","timestamp":1638782564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2013.0882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,23]]},"references-count":52,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2013.0882","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1007\/s40138-017-0123-8","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,23]]}}}